Compile Data Set for Download or QSAR
maximum 50k data
Found 1404 with Last Name = 'baker' and Initial = 'tm'
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma

US Patent
LigandPNGBDBM298445(4-((4-((4-(3-(5-(tert-Butyl)-2-methoxy-3-(methylsu...)
Affinity DataIC50:  3nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma

US Patent
LigandPNGBDBM298449(2-(2-(2-(4-((4-((4-(3-(5-(tert-butyl)-2-methoxy-3-...)
Affinity DataIC50:  4nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma

US Patent
LigandPNGBDBM337707(US10392346, Example 17(am) | US10941115, Example 1...)
Affinity DataIC50:  4nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Topivert Pharma

US Patent
LigandPNGBDBM255476(US10125100, Example 1 | US10392346, Example 1 | US...)
Affinity DataIC50:  5nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Topivert Pharma

US Patent
LigandPNGBDBM381166(US9890185, Example 79(g))
Affinity DataIC50:  5nMAssay Description:Method 2: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashion to t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Respivert

US Patent
LigandPNGBDBM381082(US9890185, Example 38(e))
Affinity DataIC50:  5nMAssay Description:Method 1: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determinin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma

US Patent
LigandPNGBDBM298426(4-[[4-[[4-[[5-tert-butyl-3-(methanesulfonamido)-2-...)
Affinity DataIC50:  5nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma

US Patent
LigandPNGBDBM298439(4-((4-((4-(3-(5-(tert-Butyl)-2-methoxy-3-(methylsu...)
Affinity DataIC50:  6nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma

US Patent
LigandPNGBDBM298442(4-((4-((4-(3-(5-(tert-Butyl)-2-methoxy-3-(methylsu...)
Affinity DataIC50:  6nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Respivert

US Patent
LigandPNGBDBM256521(US10435361, Example 20 | US9481648, 20 | US9790174...)
Affinity DataIC50:  6nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Respivert

US Patent
LigandPNGBDBM381094(US9890185, Example 38(q))
Affinity DataIC50:  6nMAssay Description:Method 1: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determinin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Respivert

US Patent
LigandPNGBDBM381167(US9890185, Example 79(m))
Affinity DataIC50:  6nMAssay Description:Method 1: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determinin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Respivert

US Patent
LigandPNGBDBM381071(1-(5-(tert-Butyl)-3-(dimethylphosphoryl)-2-methoxy...)
Affinity DataIC50:  6nMAssay Description:Method 1: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determinin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Topivert Pharma

US Patent
LigandPNGBDBM381167(US9890185, Example 79(m))
Affinity DataIC50:  7nMAssay Description:Method 2: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashion to t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma

US Patent
LigandPNGBDBM298436(2-(2-(2-(4-((4-((4-(3-(5-(tert-Butyl)-2-methoxy-3-...)
Affinity DataIC50:  8nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Topivert Pharma

US Patent
LigandPNGBDBM298436(2-(2-(2-(4-((4-((4-(3-(5-(tert-Butyl)-2-methoxy-3-...)
Affinity DataIC50:  8nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Topivert Pharma

US Patent
LigandPNGBDBM298449(2-(2-(2-(4-((4-((4-(3-(5-(tert-butyl)-2-methoxy-3-...)
Affinity DataIC50:  8nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Respivert

US Patent
LigandPNGBDBM256511(US10435361, Example 9 | US9481648, 9 | US9790174, ...)
Affinity DataIC50:  8nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Respivert

US Patent
LigandPNGBDBM337710(2-(2-(2-(4-((4-((4-(3-(5-(tert-Butyl)-2-methoxy-3-...)
Affinity DataIC50:  8nMAssay Description:The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Topivert Pharma

US Patent
LigandPNGBDBM337710(2-(2-(2-(4-((4-((4-(3-(5-(tert-Butyl)-2-methoxy-3-...)
Affinity DataIC50:  8nMAssay Description:Method 1The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Respivert

US Patent
LigandPNGBDBM381123(1-(5-(tert-Butyl)-2-methoxy-3-(methylsulfinyl)phen...)
Affinity DataIC50:  8nMAssay Description:Method 1: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determinin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Respivert

US Patent
LigandPNGBDBM347466(3-((4-((4-(3-(5-(tert-Butyl)-2-methoxy-3-(methylsu...)
Affinity DataIC50:  9nMAssay Description:TBDMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Respivert

US Patent
LigandPNGBDBM381084(US9890185, Example 38(g))
Affinity DataIC50:  9nMAssay Description:Method 1: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determinin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Respivert

US Patent
LigandPNGBDBM256515(US10435361, Example 13 | US9481648, 13 | US9790174...)
Affinity DataIC50:  9nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Respivert

US Patent
LigandPNGBDBM380997(US9890185, Example 1)
Affinity DataIC50:  9nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Respivert

US Patent
LigandPNGBDBM256509(US9481648, 7)
Affinity DataIC50:  9nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Respivert

US Patent
LigandPNGBDBM381092(US9890185, Example 38(o))
Affinity DataIC50:  9nMAssay Description:Method 1: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determinin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598412(1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598413(N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598414(1-((2-cyclobutyl-1,2,3,4-tetrahydroisoquinolin-7-y...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598415(1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598417(N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphen...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598418(N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598419(N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fl...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598420(N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphen...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598421(1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598422(N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fl...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598423(N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphen...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598424(N-{[6-(dimethyl-1,2,4-triazol-1-yl)-2-fluoro-3-met...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma

US Patent
LigandPNGBDBM298392(4-[[4-[[4-[[5-tert-Butyl-3-(methanesulfonamido)-2-...)
Affinity DataIC50:  10nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma

US Patent
LigandPNGBDBM298425(4-[[4-[[4-[[5-tert-butyl-3-(methanesulfonamido)-2-...)
Affinity DataIC50:  10nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Respivert

US Patent
LigandPNGBDBM256519(US10435361, Example 18 | US9481648, 18 | US9790174...)
Affinity DataIC50:  10nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598493(3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-met...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598500(N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598501(N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598503(N-({2-chloro-6-[3-(difluoromethyl)-1,2,4-triazol-1...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598505(N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598507(N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598508(N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM598510(N-{[2-fluoro-3-methoxy-6-(1,2,3,4-tetrazol-1-yl)ph...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 1404 total ) | Next | Last >>
Jump to: